Vinorelbine

Vinorelbine
Clinical data
Trade names	Navelbine
AHFS/Drugs.com	Monograph
MedlinePlus	a695013
Pregnancy; category	AU: D;
Routes of; administration	intravenous, by mouth
ATC code	L01CA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	43 ± 14% (oral)
Protein binding	79 to 91%
Metabolism	liver (CYP3A4-mediated)
Elimination half-life	27.7 to 43.6 hours
Excretion	Fecal (46%) and kidney (18%)
Identifiers
	IUPAC name Methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate;
CAS Number	71486-22-1 ;
PubChem CID	5311497;
DrugBank	DB00361 ;
ChemSpider	4470974 ;
UNII	Q6C979R91Y;
KEGG	D08680 ;
ChEMBL	ChEMBL607994 ;
CompTox Dashboard (EPA)	DTXSID8040640 ;
Chemical and physical data
Formula	C45H54N4O8
Molar mass	778.947 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]89C=C(CC)CN(Cc1c([nH]c2ccccc12)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@@]5([H])[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]7(CC)C=CCN6CC[C@]45[C@@]67[H])C8)C9;
	InChI InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1 ; Key:GBABOYUKABKIAF-IELIFDKJSA-N ;
	(what is this?) (verify)

Vinorelbine, sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer.^[3] This includes breast cancer and non-small cell lung cancer.^[3] It is given by injection into a vein or by mouth.^[3]^[1]

Common side effects include bone marrow suppression, pain at the site of injection, vomiting, feeling tired, numbness, and diarrhea.^[3] Other serious side effects include shortness of breath.^[3] Use during pregnancy may harm the baby.^[3] Vinorelbine is in the vinca alkaloid family of medications.^[1] It is believed to work by disrupting the normal function of microtubules and thereby stopping cell division.^[3]

Vinorelbine was approved for medical use in the United States in 1994.^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

^ ^a ^b ^c British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 594. ISBN 9780857111562.
^ Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. (November 2001). "Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors". Annals of Oncology. 12 (11): 1643–1649. doi:10.1023/A:1013180903805. PMID 11822766.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Vinorelbine Tartrate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[BNF69-1] British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 594. ISBN 9780857111562.

[Marty-2] Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. (November 2001). "Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors". Annals of Oncology. 12 (11): 1643–1649. doi:10.1023/A:1013180903805. PMID 11822766.

[AHFS2016-3] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Vinorelbine Tartrate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.

[WHO23rd-4] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1]

[2]

[3]

[4]